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Abstract
Despite great advances, molecular cancer pathology is often limited to use a small number of
biomarkers rather than the whole transcriptome, partly due to the computational challenges. Here,
we introduce a novel architecture of DNNs that is capable of simultaneous inference of various prop-
erties of biological samples, through multi-task and transfer learning. We employed this architecture
on mRNA transcription profiles of 10787 clinical samples from 34 classes (one healthy and 33 differ-
ent types of cancer) from 27 tissues. Our system significantly outperforms prior works and classical
machine learning approaches in predicting tissue-of-origin, normal or disease state and cancer type of
each sample. Furthermore, it can predict miRNA transcription profile of each sample, which enables
performing miRNA expression research when only mRNA transcriptome data are available. We also
show this system is very robust against noise and missing values. Collectively, our results highlight
applications of artificial intelligence in molecular cancer pathology and oncological research.
Keywords— Artificial intelligence, deep neural networks, multi-task learning, cancer classifica-
tion.
Introduction
Improving the accuracy of cancer diagnosis is extremely important for millions of patients and far more
non-patients who are tested every year, worldwide. Despite great advances in oncologic pathology, there
has been a significant ratio of errors that potentially affect the diagnostic results and/or treatment
strategies [1]. Our systematic search through COREMINE (www.coremine.com) revealed 7652 article
abstracts containing both neoplasms and diagnostic errors (or synonymous terms), with an increasing
trend over time. An M.D. Anderson Cancer Center study of 500 brain or spinal cord biopsies that were
submitted to their neuropathology consultation service for a second opinion revealed 42.8% disagreement
between the original and the review diagnoses, including 8.8% serious cases [2]. A study of 340 breast
cancer patients identified differences between the first and the second pathology opinions in 80% of the
cases, including major changes that altered surgical therapy occurred in 7.8% of cases [3]. A review of
66 thyroid cancer patients revealed a different pathological diagnosis of 18% of the cases [4]. A recent
study verified the accuracy and reproducibility of pathologists’ diagnoses of melanocytic skin lesions
for 240 skin biopsy cases from 10 US states and revealed 8-75% error rates in different interpretation
classes and an estimated 17.8% whole-population error rate [5]. Another recent study of 263 Australian
Lichenoid keratosis patients revealed a diagnosis failure rate higher than 70%, including 47% of the
cases misdiagnosed as basal cell carcinoma [6]. This situation is even worse in rare types of cancer. A
study of 26 patients revealed 30.8% misdiagnosis ratio in discriminating common gastric adenocarcinoma
from hepatoid adenocarcinoma of the stomach, a rare subtype of gastric cancer [7]. Accurate diagnosis
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has been also challenging for a number of cancer types, including soft tissue sarcomas that are often
misdiagnosed as other types of cancer [8].
One limitation of the current molecular pathology methods such as Immunohistochemistry (IHC)
is the limited number of genes or proteins monitored for diagnosis. Staining biopsies using antibodies
against one or two proteins cannot discriminate between different cancer types if they have similar
expression patterns of the target proteins. One possible solution is to use the whole-transcriptome
of tissue biopsies [9]. But this approach is computationally challenging and different algorithmic and
machine learning approaches have been employed so far to address this problem. A group of researches are
focused on binary classification, e.g. discriminating between normal vs. tumor samples [10, 11, 12, 13].
These methods, however, can have limited clinical applications since most of the molecular pathology
problems are multiclass, e.g. assigning each sample to one of the different cancer types. Reaching high
accuracies in classification problems usually becomes harder as the number of classes increases. Even
a random assignment of samples to two classes will achieve 50% accuracy if the classes are balanced
(i.e. there are an equal number of samples in each class), but a random classification will be around 3%
accurate if there are 33 balanced classes. Hence, it is important to consider the number of classes for
comparing the accuracies of different researches.
Optimal Feature Weighting (OFW) is one of the earliest multiclass algorithms employed for cancer
sample classification based on Microarray transcriptome. This algorithm selects an optimal discriminative
subset of genes and uses Support Vector Machine (SVM) or Classification And Regression Trees (CART).
It is employed to five different problems, each consisting of 3 to 11 classes, without explicitly mentioning
the obtained accuracies [14]. Combination of SVM with Recursive Feature Elimination (RFE) is used
to classify Microarray data of three cancer-related problems consisting of 3 to 8 classes, with accuracies
between 95% (for 8-class) to 100% (for 3-class) [15]. Greedy search over top-scoring gene-sets achieved
an average 88% accuracy, ranging from 48% to 100%, on seven different cancer datasets, each consisting
of 3 or 4 classes with 40 to 96 samples per dataset [16].
One of the largest databases of cancer transcriptome, genome and epigenome profiles is Genomic Data
Commons (GDC) that includes The Cancer Genome Atlas (TCGA) and Therapeutically Applicable
Research to Generate Effective Treatments (TARGET) programs [17]. There have been comprehensive
works to analyze GDC data from different perspectives including identification of cancer driver somatic
and pathogenic germline variations [18], oncogenic signaling pathways [19], the role of cell-of-origin [20]
and cancer stem cells [21], relationships between tumor genome, epigenome and microenvironment [18].
However, there have been limited works towards developing a molecular cancer pathology framework
out of this valuable data. DeepGene, a feed-forward artificial neural network (ANN) based classifier,
uses somatic point mutations profiles in order to assign each sample to one of 12 different cancer types.
It achieved a mean 58% and maximum 64% accuracy over 3122 TCGA samples from 12 cancer types
[22]. Another study used genetic algorithms and k-Nearest Neighbors (KNN) to classify TCGA samples
based on RNA-seq transcriptome profiles. It reached about 90% accuracy for classification of 602 normal
samples and 9096 samples from 31 tumor types [23].
Results and Discussion
Here we used Deep Neural Networks (DNNs) in a multi-task learning approach to infer different biological
and clinical information from transcriptome profiles. We designed four different architectures as shown
in Fig. 1 based on two different methods, including Contractive Autoencoder (CAE) and Variational
Autoencoder (VAE). Each of our DNNs consists of two parts that are serially connected: the encoder
part, that learns to convert a given mRNA expression profile (mRNA EP) of a clinical sample at the
input layer to a latent representation, which we call it Cell Identity Code (CIC), and the decoder part
that infers multiple outputs from the CIC. While the CIC is a simple vector of numerics in the CAEs,
the VAEs encode the input to two equal-size vectors, which represent means and standard deviations
of multiple Gaussian distributions. For each method, we designed two architectures, one simpler and
another consisting of dropout normalizers after each layer of the encoder. To make our architectures
resistant to missing values and noisy data, we added a Gaussian Dropout layer after the input, which
perturbs the data with a Gaussian noise and randomly sets some input values to zero. More details are
provided in the online methods.
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What makes our architectures different from conventional autoencoders is its particular design to
learn useful latent representations of the input data. Altered weights of the encoder part result in
different latent representations of the same input, which can be decoded to the same output by different
decoder weights. Hence, there is an infinitely large number of latent representation sets for a given set of
data, however, the question is whether all of these representations are useful. Some latent representations
might be extremely cryptic, while the others might be very useful for classification of biological samples,
or obtaining other information. For instance, classification would be much easier if all cells of each type
cluster together, distantly from the other clusters, in the latent representation space. The challenge is
how to train the network in order to learn useful latent representations of the mRNA EPs.
To address this challenge, we designed the decoder part of each network to simultaneously learn
four different classification and regression problems using the CIC, in a multi-task learning scheme: (i)
reproducing mRNA EP as one of the outputs that is as close to the original mRNA EP in the input
as possible, (ii) predicting a miRNA expression profile (miRNA EP) that is as close as possible to the
experimentally measured miRNA EP of the same sample, (iii) predicting the sample tissue of origin,
among 27 different tissues, and (iv) predicting the sample disease state, which can be either normal or
one of 33 different cancer types.
From the above tasks, (i) and (ii) can be viewed as non-linear regression, and (iii) and (iv) are
classification. Importantly, the multi-task learning part of the DNN is aimed to accomplish all of these
tasks only by getting the CIC as the input. Task (i) is to ensure the CIC stores much of the information
in the original mRNA EP. Due to task (ii), we selected from GDC a subset of 10787 having both mRNA
and miRNA EPs available. Furthermore, we removed ll miRNA-encoding genes from the mRNA profiles,
to make this task non-trivial.
The other key advantage of our model is hyperparameter optimization. In addition to the internal
network parameters (i.e. synapse weights and neuron bias values), each network has a set of hyperparam-
eters, including the number of neurons in each layer, activation functions, size of mini-batches, standard
deviations of the Gaussian noises, ratios of dropout layers, and the number of training epochs. Altered
values of hyperparameters greatly affect the network results. Due to their cryptic inter-dependencies, all
hyperparameters are required to be optimized simultaneously. For this purpose, we performed a compre-
hensive hyperparameter optimization through a Bayesian approach that runs in a number of iterations.
In each iteration, it tries to find a set of hyperparameters that has the maximum likelihood of optimizing
the network training outcome by integrating the results of all previous iterations in a Bayesian model.
This process has superior advantages over grid search or random search of the hyperparameters in re-
ducing the search space and more direct approaching the optimal hyperparameters using much fewer
iterations.
As shown in Fig. S5, both network architecture and hyperparameters have a big impact on the
regression and classification results. The red values in Fig. 1 depict the optimal hyperparameter values.
Surprisingly, a vector of length eight was optimal as the CIC of the Dropout-CAE, which outperformed
the other networks in regression and classification tasks. It means a set of eight numeric values is sufficient
to represent almost the whole transcriptome profile and critical features of a biological sample.
We trained the hyperparameter optimized networks for 200 epochs using the training dataset. Fig. S6
shows the performance of these networks on the training dataset during the training, and Fig. S7 shows
their performance on the test dataset. The CAE and Dropout-CAE architectures depicted the best
performance in all four tasks. For the regression tasks (i.e. reproducing the mRNA and predicting the
miRNA EP) the CAE architecture had a slightly better performance over the Dropout-CAE, but for the
classification tasks, both networks performed very similarly. Furthermore, there was no sign of overfitting
for these architectures as the test dataset errors did not increase during the training. Also, all accuracies
and MSEs reached stable levels, that showed 200 training epochs was sufficient.
We compared the classification accuracy of our method with several other widely-used classification
algorithms. For this purpose, we selected k-nearest neighbors (KNN), Extra Tree, Random Forest,
and Stochastic Gradient Descent (SGD). To have a fair comparison, we also performed hyperparameter
optimization for each of these algorithms. As shown in Fig. 2a, our Dropout-CAE network outperformed
the other classification algorithms in identifying the tissue of each sample. Fig. 2b shows a tiny number
of misclassification in the confusion matrix of the Dropout-CAE. Figs. 2c,d show similar results for
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cancer type classification. To ensure the results are not overfitted to a particular subset of the data,
we performed a 10-fold cross-validation and measured different accuracy criteria for tissue and disease
classification. The data was shuffled and each sample was randomly assigned to one of 10 groups. In i-th
round of cross-validation (1 ≤ i ≤ 10), group i was used as the test set and the remaining nine groups
were used for training. The results are depicted in Fig. 3.
The balanced accuracy of tissue classification was ≥ 99% for 14 tissues, and ≥ 95% for 25 out of
27 tissues. This showed the DNN results are stable across different tissue types. Disease classification
was ≥ 99% accurate for 9 cancer types, and ≥ 95% for 25 cancer types and normal tissues. Only 3
out of 33 cancer types had a balanced accuracy less than 90%. The standard error among 10 rounds of
cross-validation was negligible for most of the tissues and disease types. These analyses confirmed our
method is not overfitted towards a particular tissue or disease type or some subset of the data.
Fig. 3c,d show sensitivity and specificity of DNN in disease classification. We observed an average
sensitivity ≥ 99% and ≥ 95% for 6 and 18 cancer types, respectively. Seven cancer types had a sensitivity
lower than 90%. The specificity was ≥ 99% for all 34 classes, including 33 cancer types and 1 normal
tissues.
A potential issue with classifiers is their reduced accuracy when the input data are noisy or have
missing values, due to sample quality or measurement errors. To check the effect of missing values, we
added a dropout layer after the input that randomly dropped the expression values of a random set of
genes by setting them to zero. The fraction of dropout genes was increased from 0 to 50% with 1%
steps. The results are presented in Fig. 4a. In each plot, the x-axis shows the fraction of dropout genes,
and the y-axis shows either regression MSE or classification accuracy for the test dataset. As shown,
dropping the values of 50% of the genes has a negligible effect on reproducing mRNA expression profiles,
with almost no MSE change for all architectures excepting Dropout-VAE. Interestingly,the increased
dropout rate caused improved MSE for Dropout-VAE. Increasing the dropout rate elevated the MSE of
predicting miRNA EP for all DNN architectures. But even at 50% dropout, the MSE of all architectures
was around 0.004, which is quite small.
The classification accuracies of all DNN, particularly the Dropout-CAE and Dropout-VAE had small
changes by increasing the missing values from 0 to 20%. Even at 30% dropout rate, Dropout-CAE was
95% accurate. Disease classification accuracy of both Dropout-CAE and Dropout-VAE had also small
changes by a dropout rate up to 20%. These experiments showed that the DNN architectures that
contained Dropout layer had the highest resistance to missing values.
We also measured the resistance of DNNs to a noisy input (Fig. 4b). A layer just after the input added
a zero-mean Gaussian noise to the input GEPs. The magnitude of the noise was controlled by increasing
its standard deviation (SD) from 0 to 0.25 with 0.01 steps. Both CAE and Dropout-CAE architectures
were quite resistant to noise in reproducing the mRNA EP, and their MSEs were almost unchanged at
SD=0.25. All networks could predict miRNA EP with MSE ≤ 0.01 when the SD of Gaussian noise was
at most 0.08. But their errors were increased by increasing the noise magnitude. The tissue and disease
classification accuracies of Dropout-CAE were almost unchanged for a noise SD ≤ 0.05. Dropout-CAE
and Dropout-VAE outperformed the other architectures in resisting against Gaussian noise.
Collectively, our results indicate the power of DNNs in obtaining biologically and clinically impor-
tant information from transcriptome profiles. Our networks compress the transcriptome profile into a
thumbnail CIC, and obtain tissue and disease type and miRNA expression profile out of it. This process
is greatly robust against noisy and missing data and outperforms the other algorithms in accuracy. We
suggest employing DNNs in inferring the outcome of molecular cancer pathology.
ONLINE METHODS
3.1 Data
Transcriptome profiles of 11,500 samples were obtained from the Genomic Data Commons (GDC) con-
sortium [17], including The Cancer Genome Atlas (TCGA) [18] and the Therapeutically Applicable
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Research to Generate Effective Treatments (TARGET) databases. For each mRNA profile, its corre-
sponding miRNA profile was needed to train the model. So we kept the samples that both mRNA and
miRNA expression profiles were available. This resulted in a total number of 10787 samples, including
10150 tumor and 637 normal samples. The mRNA and miRNA profiles of each sample were matched by
the ID values of the patients, using the TCGAbiolinks R/Bioconductor package [24].
3.2 Deep Autoencoder
An interesting Neural Network (NN) architecture is autoencoder (AE), which compresses the input into
a latent space representation, and then reconstructs the input back from this representation. In other
words, an AE seeks to learn an identity-like mapping function f such that f(x) ≈ x. AEs can reduce
the dimensionality of data without losing significant information and can be unsupervisedly trained
using unlabeled data, hence they are widely used in different problems including data compression,
dimensionality reduction, manifold learning, and feature learning [25].
Each autoencoder consists of two parts, the encoder and the decoder, which can be defined as tran-
sition functions f and g such that:
f : χ→ F
g : F → χ
f, g = arg min
φ,ψ
J (x, x˜(φ, ψ, x))
where ψ and φ are the encoder and the decoder functions, respectively, x˜(φ, ψ, x) = φ ◦ ψ(x) is the
reconstruction of input vector x and J = ∑
x∈D
L(x, x˜(φ, ψ, x)) is the total loss, which is evaluated as the
summation of reconstruction error L on training dataset D.
3.3 Autoencoders variants
While training an AE, we aim not only to reconstruct the input from the latent representation, but
also to extract beneficial features in this representation. Therefore, it is vital to utilize some forms of
regularization techniques to avoid overfitting or useless representations, even if the AE can reconstruct
the input with minimal loss [25, 26]. Different regularization techniques can veritably produce different
variations of objective functions, and subsequently different features extracted from the data. The next
sub-section explains the autoencoder variants of this study.
3.3.1 Denoising Autoencoder
A beneficial form of regularization is used in denoising autoencoders (DAE), where the input vector
x is slightly corrupted and the autoencoder is expected to reconstruct the clean data from the latent
representation [27]. As a result, the DAE learns to resist against input noise and overfitting. The
following objective function is used for training DAEs:
J =
∑
x∈D
Exˆ∼q(xˆ|x)L(x, x˜(φ, ψ, xˆ)) (1)
where the expectation is evaluated over the corrupted versions xˆ of the original data x, obtained from a
corruption function q(xˆ|x). This objective is optimized by stochastic gradient descent (SGD) or another
iterative optimization algorithm. Additive isotropic Gaussian noise and binary masking noise are among
the most frequently used corruption processes.
Dropout [28, 29] is another regularization technique that introduces some noise to the nodes of any
hidden layer, in contrast to the DAE that adds noise only to the input layer. The foremost dropout
techniques utilized in deep learning are Bernoulli and Gaussian. In the former case, the output values of
individual nodes are either dropped to zero with a probability 1−p, or kept unchanged with a probability
p. In the latter case, a multiplicative one-centered Gaussian noise N (1, σ2) is applied to the output values
of the nodes.
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3.3.2 Contractive Autoencoder
An alternative regularization technique is used in contractive autoencoder (CAE). If h = ψ(x) is the
latent representation of the input data x, the regularization term in CAE is the total squares of all partial
derivatives of h with respect to each dimension of the previous layer; therefore, the objective function of
a CAE is expressed as:
J =
∑
x∈D
L(x, x˜(φ, ψ, x)) + λ‖Jψ(x)‖2F (2)
Where the penalty term ‖Jψ(x)‖2F is the Frobenius norm of the Jacobian matrix of the encoder
activations with respect to the input, and λ is a balancing factor. The main goal of this term is to
enforce the learned representation to be robust against small variations in the input data.
3.3.3 Variational Autoencoder
Variational autoencoder (VAE) is a special type of autoencoder with additional constraints on the en-
coded representations. It assumes that a latent, unobserved random variable z exists, which can leads
to the observations x by some stochastic mapping. As a result, its objective is to approximate the
distribution of the latent variable z given the observations x.
VAEs replace deterministic functions in the encoder and decoder by stochastic mappings; and compute
the objective function in virtue of the density functions of the random variables:
J (φ, θ, x) = DKL(qφ(z|x)‖pθ(z))− Eqφ(z|x)(log(pθ(x|z))) (3)
Where DKL stands for the KullbackLeibler divergence, and q is the distribution approximating the
true latent distribution of z, and θ, φ are the parameters of each distribution. The prior distribution
over the latent variables is generally set to standard multivariate Gaussian pθ(z) = N (0, σ2I); however,
alternative distribution have also been recently considered.
Although AEs can not generally be able to construct meaningful outputs from arbitrary encodings,
VAE can learn a model of the data that can generate new samples from scratch by random sampling
from the latent distribution. Therefore, VAEs are among the generative models.
3.4 Models Architecture
Our problem consists of two regression, namely reproducing mRNA and miRNA profiles from the latent
variables, and two classification tasks to determine the tissue and disease state of each sample. All mRNA
and miRNA expression profiles were normalized in [0, 1] by max-norm method of Scikit-Learn package
[30]. We subsequently constructed the multi-input and multi-output models in Keras [31]. Keras is a
high-level Python NN library that runs on top of either TensorFlow [32] or Theano [33].
We constructed four different NN architectures:
• Variational autoencoder (VAE)
• Dropout-VAE, an extension of VAE with Bernoulli and Gaussian dropout layers being utilized for
denoising.
• Contractive autoencoder (CAE)
• Dropout-CAE, the extended CAE with Bernoulli and Gaussian dropout layers.
To make each network tolerate input noise, an optional Gaussian noise N (0, σ2) can be added to the
input.
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3.5 Loss Functions
We utilized cosine similarity as the loss for the classification tasks. Another choice was categorical cross
entropy, but we preferred to use the former function since it provides bounded results, which can be easily
used in hyperparameter optimization. We also used mean squared error (MSE) as the loss function for
the regression tasks. The total loss in our multi-task learning problem was be the weighted sum of
individual losses, where the weights were 5 × 10−1 for each classification task, and 1 × 10−3 for each
regression task. To evaluate the model performance in the validation dataset, we used used accuracy as
the classification metric, and MSE and mean absolute error (MAE) for the regression tasks.
3.6 Batch Normalization
A major issue in training the DNNs is altered distribution of each layer inputs, as the weights and other
parameters of the previous layers change. As a result of this internal covariate shift, the learning rate
should be lowered that causes reduced training speed rate, and also the initialization parameters should
be assigned carefully [34]. A well-known approach to address these challenges is batch normalization.
Let’s x1···m be the values of an activation x during a mini-batch. Then the batch normalized values
y1···m are computed as follows:
yi = γ
xi − µ√
σ2 + 
+ β (4)
where µ and σ2 are the mean and variance of the x1···m values, γ and β are the scaling parameters
to be learned, and  is a small constant value added to the mini-batch variance for numerical stability.
This method basically standardizes the inputs of each layer in such a way that they have a mean
and standard deviation of zero and one, respectively. Then scales the standardized values by a linear
function, with parameters that are learned. Batch normalization is analogous to how the inputs to the
networks are standardized, but it can be performed for each internal layer of a DNN. It turns out that,
extending this technique to hidden layers can significantly improve the training speed.
As depicted in Fig. 1, each building layer of our network is consisted of a batch normalization layer,
followed by a dense layer. Our experience showed the batch normalization layers significantly improve
the training speed of the networks.
Hyperparameters Tuning
Many machine learning methods have a set of architectural parameters, called hyperparameters, which
are determined prior to training the model. For example, the number of layers, the number of neurons
per layer, the type of activation functions, and the type of dropout or noises are among the DNN
hyperparameters. Since the values of hyperparameters affect the model architecture, hyperparameter
optimization can be considered as model selection technique.
A key advantage of our work is optimizing the network hyperparameters in order to achieve the best
classification and regression objectives. Besides two simple methods of hyperparameter tuning including
grid search and random search, there exists a more advanced Bayesian algorithm [35].
Bayesian optimization, in contrast to random or grid search, keeps track of the past evaluations
and utilizes them to define a probabilistic model mapping hyperparameters to a probability distribution
of the outcome of the objective function P (s|h), where s and h are the objective function score and
hyperparameters. This is called a surrogate model for the objective function, and is easier to be optimized
in comparison with the objective function itself. In each iteration, the Bayesian optimization selects
optimal hyperparameters based on the surrogate function as the next set of hyperparameters to be
evaluated by the actual objective function. Briefly, it works as the following algorithm:
1. Build a surrogate probability model of the objective function.
2. Find the hyperparameters that perform best on the surrogate.
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3. Evaluate these hyperparameters by the actual objective function.
4. Update the surrogate model by incorporating the new results.
5. Repeat steps 24 for the specified number of iterations or running time.
The main advantage of the Bayesian optimization is becoming more intelligent by continuously up-
dating the surrogate probability model after each evaluation of the objective function. By intelligently
selecting hyperparameters that are more likely to optimize the objective function in each iteration, they
can find better set of hyperparameters in a fewer iterations, in comparison with random and grid search
[36, 37].
To exploit Bayesian optimization in our model selection procedure, we utilized a Python module
called Hyperopt [38]. Hyperopt provides efficacious algorithms and parallel infrastructure.
We needed to define a search space and an objective function for the hyperparameter optimization.
The next sub-section explains the search space. As the objective function, we used an average of the
total losses of all data, that was split to 90% training and 10% validation.
While we benefited from all data in hyperparameter optimization, we performed 10-fold cross-
validation while measuring classification accuracies to ensure the hyperparameters are not overfitted
to some specific portion of the data.
4.1 Hyperparameters Search Space
For each architecture, we selected a set of hyperparameters; and for each hyperparameter, we defined a
set of discrete values as the search space. The Cartesian product of all of these search spaces was used
as the total search space of the hyperparameter optimization process.
Below is a description of the hyperparameters:
• Units: A critical feature of each layer is the number of its neurons. Based on our experiences in
a prior work, we selected a wide range of different values as the search space of each layer. These
values were selected in a decreasing order for the encoder part, to gradually narrow it down from
the input to the latent (code) layer, followed by an increasing order in the decoder part.
• Activation Functions: A widely used activation function is Rectified Linear Unit (ReLU), which
is defined as f(x) = max(x, 0) [39]. Since gradients can readily flow whenever the input to the
ReLU function is positive, gradient descent optimization is much simpler for ReLU than sigmoidal
activation functions. Although a few efficacious activation functions such as Swish [40] and Selu [41]
have been recently introduced; However, there has been no significant and universal enhancement
to utilize them instead of ReLu function.
Despite promising features, ReLU can cause some difficulties in autoencoders; including gradient
explosion and saturation. Hence we additionally used linear activation functions f(x) = x and
SoftPlus activation function f(x) = ln(1 + exp(x)), as comprehensively discussed [42].
• Dropout Rate: Dropout layer plays an important role by acting as regularizer to prevent overfit-
ting. It has one main tunable parameter, which is the noise rate. We chose {0, 0.25, 0.5} as the set
of noise rates. By putting 0 in the options, we provided Dropout-CAE and Dropout-VAE models.
By this way, these models become more flexible to either exploit or not to exploit dropout layers
into their own structures to achieve the maximum performance.
For each NN architecture, we set Hyperopt to iterate over 200 different networks and select the best one
among them.
4.2 Comparison Between Algorithms
We compared the classification accuracy of the proposed deep learning method against other classification
methods including KNN, Extra Tree Classifier, Random Forest Classifier, and SGD Classifier. We
selected these algorithms because they were available for parallel execution in Scikit-Learn package [30].
Moreover, they are among the most efficient and versatile classification algorithms.
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To ensure the hyperparameters of the other classifiers are selected properly, we performed 100 itera-
tions of hyperparameter optimization on each classification algorithm (Fig. S8). The results are shown
in Fig. 2a,c. As shown, our method has outperformed the other classification algorithms in both tissue
and disease prediction.
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Fig. 1: Architectures of MLAEs of the study 
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Figure 1: Different architectures of DNN used for this study. (a) Contractive Autoencoder (CAE), (b)
Dropout Contractive Autoencoder (Dropout-CAE), (c) Variational Autoencoder (VAE), (d) Dropout
Variational Autoencoder (Droput-VAE). For each network, the layers are shown as boxes and the con-
nections between them as arrows. The evaluated hyperparameters of each layer are shown next to each
layer. The hyperparameter values in red show the optimal parameters identified through hyperparameter
optimization. See extended methods for more details.
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Figure 2: Accuracy of the DNN, in comparison with other classifier algorithms. (a) Each violin shows
the distribution of tissue classification accuracies obtained by hyperparameter optimization of different
algorithms. The leftmost violin shows our algorithm, and the other violins show some widely-used
classification algorithms. (b) Confusion matrix of tissue classification, in which the x and y axes represent
the actual and predicted tissue types. Each cell contains zero or some positive number of samples, and
the diagonal and other cells represent correct and incorrect classifications, respectively. (c, d) Similar
analyses for classification of the disease type.
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Fig. 2: Architectures
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Figure 3: Performance of DNN in the classification of different tissues and diseases. (a) Balanced accu-
racy of tissue classification. (b) Balanced accuracy of disease classification. Healthy samples are depicted
as ”Healthy”. (c,d) Sensitivity and specificity of disease classification. All analyses are performed using
10-fold cross-validation. Error bars indicate standard error (SE).
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Fig. : Robustness of the deep neural network against dropout and noise.
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Figure 4: The resistance of different DNN architectures against missing values and noise. (a) In each
plot, the x-axis shows the fragment of randomly-selected input values that are set to zero (dropout),
and y-axis shows either regression MSE or classification accuracy for the test dataset. (b) The x-axis
shows the standard error (SD) of a zero-centered Gaussian noise which was added to the input values,
and y-axis shows MSE or accuracy for the test dataset. Colors indicate different DNN architectures (see
the figure legend).
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Fig. 2: Hyper-parameter optimisation results
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Figure S5: Distribution of different error or accuracy measurements during hyperparameter optimization:
(a) mean square error (MSE) of reproducing mRNA expression profiles (EP), (b) MSE of generating
miRNA expression profiles, (c) mean absolute error (MAE) of reproducing mRNA EP, (d) MAE of
reproducing miRNA EP, (e) accuracy of predicting tissue for the test dataset, (f) accuracy of predicting
cancer type for the test dataset. In each violin plot, the colors represent different architectures.
17
●●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●
●
●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●●
●
●●
●
●
●●
●●
●●●●●●●●
●●●●●●● ●●● ●
● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●● ●
● ●●●● ● ●
● ●
●●●●●●●●●●●●●
●●●●●●●●
●
●
●
●
●
●
●
●
●●
●
●●●●●●● ●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●
●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
● ●●●●●●●●
●●●●●●
●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●●●●●●●●●●●●●●●●●●●●●● ●
●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●
mRNA EP miRNA EP
0 50 100 150 200 0 50 100 150 200
0.000
0.002
0.004
0.006
0.008
0.000
0.002
0.004
0.006
0.008
Epoch
M
SE
 (t
ra
in)
Model
●
●
●
●
CAE
Dropout−CAE
VAE
Dropout−VAE
●
●
●
●
●●
●
●●●●●●●●●●●●●●●●●
●●●●●●●
●
●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●
●
●●●
●
●● ● ●● ●
●
●● ● ● ● ●●● ●●●● ● ●● ● ●●●●● ● ●● ● ● ●● ●● ●● ● ● ● ●●● ● ● ●●●
●
●
●
●
●● ●●
●●●
●●
●●●●●●●●●●●●
●●●●●●●●●●
●●●●●●
●
●
●
●●●●●
●
●
●●●●● ●●●
●●●●●●●●
●●●●●●●●●
●●●●●●●●●●
●●
●●
●●●●●●
●●●●
●
●
●●●●●●●●●●
●●●●●●●
●
●●●
●●
●
●
●●
●
●
●
●●
●●●●
●●
●
●●
●●●●●●
●●●●●●
●
●●●
●●●●●●●
●●●●●●
●●●●●●●
●●●●●●
●●●●●●
●
●●●●
●
●
●
●
●
●
●
●●
●●●●●
●●●●
●
●●●●●●●●●
●●
●●●●●●●
●
●●●
●●
●●
●
●●
●●
●
●●●
●
●●●
●●●●●●
●●
●
●●●●●●●●●●
●
●●
●●●●●●●
●●●
●●●
●
●●
●●●●●●●
●
●●
●
●
●●●
●
●●●●●
●
●●
●
●
●●●●●●●●●●
●
●●●●●●●●●●●●●
●●●●●●●
●
●●
●●
●●●●
●
●
●●●●
●●
●
●
●●●●●
●
●●●
●
●
●
●●●●●
●
●●
●●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●●●●●●●●●●●●●●●
●●●●●●●●●
●●●●●●●●●
●●●●●
●●●●●●●●●
●●●●●●●
●●●●●●●●●●●●●●●●●●●●
●
●●●
●●
●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●
●
●
●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●
●●●
●●●●●●●●●●●●●●●●
●●●
●
●
●
●
●
●
●
●
●
●●●●
●●
●
●
●●●
●●●●
●
●●●●●●●●●●●●●●●●●●
●
●●●●●
●
●●●●●●
●
●● ●●●●●● ●●●● ●●●● ●●●●●●●●●●●●●●●● ●●●●● ●
● ●●●● ●●● ● ●●●●●●● ●● ● ●
●● ●●●● ●● ●● ● ● ●●● ●
●
●
●
●
●
●
●●●
●
●
●●●
●●●●
●●●●
●
●●
●
●●●
●
●●
●●●
●●
●●
●●●●
●
●
●●●
●
●●
●●
●●●
●
●●●●
●
●●
●●●
●
●●●
●
●
●●●●
●
●
●
●●
●●●●●●●
●
●
●
●●●●
●
●●●
●
●
●
●
●
●
●
●●●
●
●●●
●
●●
●
●
●
●●●●
●
●
●
●
●●
●●
●
●
●
●
●●●
●●
●●●●
●
●
●●●
●●
●
●
●●●●
●
●
●
●●
●
●●●●●
●●●
●
●●
●
●●●
●
●
●
●●●
●●
●●
●
●●
●
●
●●●●
●●
●
●
●
●
●
●
●
●●●
●●●●
●●●●●
●●●
●●●●●●
●●●●●●●●●●●●●●●●
●●●●●
●●
●●●
●
●
●
●●●
●●●●
●
●
●●●
●●
●●
●●●●●●
●●●●●●●●
●●
●
●●●
●●●
●●●
●
●
●●
●
●
●●●●
●
●
●●
●●
●
●●
●
●●●
●
●●●
●●●●
●
●●●●
●●●
●
●●●●●●●
●●●●
●
●●
●
●●●
●
●●
●●
●
●
●
●●●●●●
●
●
●
●●●
●
●●
●●●
●
●
●●●●●●
●
●
●
●●
●
●
●●
Tissue Disease
0 50 100 150 200 0 50 100 150 200
−1.0
−0.9
−0.8
−0.7
−0.6
−0.5
−1.0
−0.9
−0.8
−0.7
−0.6
−0.5
Epoch
Lo
ss
 (t
ra
in)
Model
●
●
●
●
CAE
Dropout−CAE
VAE
Dropout−VAE
●
●
●
●
●●
●
●●
●●●●●●
●●●●●●●
●●●●●
●●●●●●●●
●●●●●●●●
●●●●●●●●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●
●
●
●●
●
●● ● ●
● ●
●
● ●● ● ●●● ●●● ● ●
● ● ● ●● ●●●●● ● ●● ● ●●●● ●● ●●
●● ● ● ● ● ● ● ●●● ●●
● ●● ● ●●● ●
●
●
●
●
●
●●
●●●
●
●●●
●●●●
●
●
●●●●●●●●●●
●●●●●●●
●
●●●●●●●
●
●
●●●●●●
●
●●
●●
●●●●●●●●
●●●●●●●
●●●●●●●●●●●
●●●●●●
●●
●●
●●●●●●●
●●●●
●
●●
●●●●
●●●●
●●●
●●●●
●
●●
●
●●
●
●
●●
●
●
●
●●
●●●●●●
●
●●
●●●●●●●●●●●
●
●
●●
●
●●●●
●●●
●●●●●
●
●●●●
●●●●●●●●●●●●
●●●
●
●●●●
●
●
●
●
●
●
●
●●
●●●
●●
●●
●●
●
●●
●●●●●●●
●●
●
●●
●●●
●
●
●●●●●
●●●
●●
●
●
●
●●●
●
●●●
●●
●●●●●●
●
●●●
●●●●●●
●
●
●
●●●
●●●●●●
●●●●
●
●●
●
●●
●●●●●●
●●
●
●
●●●
●
●●●●●●
●●●
●
●
●●●
●●●●
●●
●
●●●
●●●●●
●●●●●
●●
●●●●●●
●●●●
●●
●●
●
●
●●●
●
●●
●
●
●●
●●●
●
●●●
●●
●
●●●
●●
●
●●
●●
●●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●●
●●●●
●●●
●
●●●●
●●●●●
●●●●●●
●
●●●
●●●●●●
●●
●●●
●●●
●●●●●●●
●●●●●●
●●
●●●●●●●●●●
●●●●●
●●●
●
●●●
●●
●●●●●●●
●●●●●●●●●●
●●●●●●●●
●●●●●●●●●●●●●●
●
●
●●●●●●●●●●●●●●●●●
●●●●●
●●●●●●●●●●●●●●●●●●●●
●●●
●●●●●●●●●●●●●●●●●●
●
●
●
●
●
●
●
●
●
●●
●●
●●
●
●
●●
●
●●●
●
●
●●●●●●●
●●●
●●
●
●
●●●●
●
●●●
●●● ●●●●●
●●
●●● ●
●●●●● ●●●●
●●●● ●●●●●●●●●●
●●●●●●● ●●●●●
●●● ●●
●● ●●● ● ●●●●●●● ●
●●● ●
● ●●●
●●●● ●● ● ●●●● ●● ● ● ●●● ● ● ● ●
●
●
●
●
●
●
●●●
●
●
●●●
●●●●
●
●
●●●●
●
●
●●●
●
●●●●●
●●
●●●●●●●
●
●●
●
●
●●●
●●●●●
●●●
●
●
●●
●●●
●
●●●●
●
●●
●●
●
●
●
●●
●●
●●●●●●
●
●
●●●
●
●
●●●
●
●
●
●
●
●
●
●●●
●
●●
●
●
●●
●
●
●
●●●●●
●
●
●
●●
●●
●
●
●
●
●●●●●●●●●
●
●
●●●●●
●
●
●●●●
●
●
●
●●
●
●●●●●
●●●
●
●●
●
●
●●●
●
●
●●●
●●
●●
●
●●
●
●
●●●●
●●
●
●
●
●
●
●
●
●●
●●
●●●
●●
●●
●
●●●
●●●●●●
●●●●●
●●●●●●●●●●
●
●●●
●●
●●
●●●
●
●
●
●●●
●
●●●
●
●
●●●●●
●●●●●●●
●
●●●●●●
●●
●●
●
●●●
●●
●
●
●●
●●
●●●
●
●●
●●●
●
●●
●●
●
●●
●●●●
●
●●●●●●●
●
●●●
●
●●
●
●
●●●
●●●
●
●●
●●
●
●●
●
●●
●
●
●●
●●
●
●
●●●●
●●●●
●
●
●●●
●
●●
●●●
●
●
●●●●●●
●
●
●
●●
●
●
●●
Tissue Disease
0 50 100 150 200 0 50 100 150 200
0.5
0.6
0.7
0.8
0.9
1.0
0.5
0.6
0.7
0.8
0.9
1.0
Epoch
Ac
cu
ra
cy
 (t
ra
in) Model
●
●
●
●
CAE
Dropout−CAE
VAE
Dropout−VAE
Fig. S1 : Training of the hyper-parameter optimised architectures
a b
c d
e f
●
●
●
●
●
●
●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●
●
●
●
●
●
●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●
●
●
●
●●●
●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●
●●●●●●●●●●●●●●●●●●●
●●●●●●
●
●
●
●
●
●
●
●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●● ●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●● ●● ●●●● ●● ● ●●●● ●● ●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ● ●●●●●●●●●● ● ●●●●● ●●●●●●● ●●●●● ●●●●●●●●●●●●●●●● ●●●●●●●●
●
●
●
●●●●●●●● ● ●● ● ●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●● ●● ●
● ●●●●●●●●●●●●●
●●●●●●●●●●●●●
●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●
●●●●●●
●●●●●●●●●
●●●●
●
●●●●●
●
●
●
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
●●●●●●●●●●●●●●●●●●●
●
●●●●●
mRNA EP miRNA EP
0 50 100 150 200 0 50 100 150 200
0.0025
0.0050
0.0075
0.0100
0.0125
0.0025
0.0050
0.0075
0.0100
0.0125
Epoch
M
SE
 (t
es
t)
Model
●
●
●
●
CAE
Dropout−CAE
VAE
Dropout−VAE
Figure S6: Performance of DNNs on training data, during 200 epochs of training. In each plot, the x-axis
shows the training epochs, and the y-axis shows: (a) the value of loss function for predicting tissue type,
(b) the value of loss function for predicting disease state, (c) mean square error (MSE) of reproducing
mRNA expression profiles (EP), (d) MSE of predicting miRNA EP, (e) accuracy of predicting tissue,
and (f) accuracy of predicting cancer type. All results are based on the training dataset.
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Fig. S1 : Test of the hyper-parameter optimised architectures
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Figure S7: Performance of DNNs on test data, during 200 epochs of training. In each plot, the x-axis
shows the training epochs, and the y-axis shows: (a) the value of loss function for predicting tissue type,
(b) the value of loss function for predicting disease state, (c) mean square error (MSE) of reproducing
mRNA expression profiles (EP), (d) MSE of predicting miRNA EP, (e) accuracy of predicting tissue,
and (f) accuracy of predicting cancer type. All results are based on the test dataset.
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Figure S8: Hyperparameter optmization of the other classification algorithms. Here the notation [start :
step : end] return evenly spaced values within the close interval [start, stop] with increments equal to
step. A dictionary {a, b, c} means that all of the item a, b, and c can be selected in the Bayesian
optimization process.
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